https://www.socictopen.socict.org/files/original/da3b668a61f0601dc17d5d9032bb6e4e.pdf 97d0f690c062a08486f813b9feed4328 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study Creator An entity primarily responsible for making the resource Carmine Sellitto, Amelia Filippelli, Carolina Vitale, Angelantonio Maglio, Carmine Selleri, Alessandro Vatrella, Carmine Vecchione, Anna Borrelli, Bianca Serio, Valentina Giudice, Alfonso Masullo, Pasquale Pagliano, Sergio Poto, Benedetto Maria Polverino, Renato Gammaldi, Bianca Cuffa Description An account of the resource To date, there are no specific therapeutic strategies for treatment of COVID-19. Based on the hypothesis that complement and coagulation cascades are activated by viral infection, and might trigger an acute respiratory distress syndrome (ARDS), we report clinical outcomes of 17 consecutive cases of SARS-CoV-2-related ARDS treated (N = 7) with the novel combination of ruxolitinib, a JAK1/2 inhibitor, 10 mg/twice daily for 14 days and eculizumab, an anti-C5a complement monoclonal antibody, 900 mg IV/weekly for a maximum of three weeks, or with the best available therapy (N = 10). Patients treated with the combination showed significant improvements in respiratory symptoms and radiographic pulmonary lesions and decrease in circulating D-dimer levels compared to the best available therapy group. Our results support the use of combined ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related ARDS by simultaneously turning off abnormal innate and adaptive immune responses. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource Eculizumab, JAK-Inhibitor, ARDS (Acute respiratory distress syndrome), SARS-CoV-2, COVID-19 Identifier An unambiguous reference to the resource within a given context DOI: 10.3389/fphar.2020.00857 Source A related resource from which the described resource is derived Frontiers in Pharmacology Publisher An entity responsible for making the resource available Frontiers Media S.A. Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Therapeutics. Pharmacology